BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price target of ...

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

One year after its initial public offering, Helix Acquisition Corp. II is now helping another biotech company go public.

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report issued on Monday, February 24th. Leerink Partnrs analyst M.

BridgeBio Oncology Therapeutics, a company working to advance the field of therapies addressing a validated but elusive group of cancer targets, has reached a deal to go public in a SPAC merger ...